BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32198576)

  • 1. Extramedullary Disease in Multiple Myeloma.
    Jagosky MH; Usmani SZ
    Curr Hematol Malig Rep; 2020 Apr; 15(2):62-71. PubMed ID: 32198576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients.
    Avivi I; Cohen YC; Suska A; Shragai T; Mikala G; Garderet L; Seny GM; Glickman S; Jayabalan DS; Niesvizky R; Gozzetti A; Wiśniewska-Piąty K; Waszczuk-Gajda A; Usnarska-Zubkiewicz L; Hus I; Guzicka R; Radocha J; Milunovic V; Davila J; Gentile M; Castillo JJ; Jurczyszyn A
    Am J Hematol; 2019 Oct; 94(10):1132-1140. PubMed ID: 31334859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    Gagelmann N; Eikema DJ; Koster L; Caillot D; Pioltelli P; Lleonart JB; Reményi P; Blaise D; Schaap N; Trneny M; Passweg J; Porras RP; Cahn JY; Musso M; Poiré X; Fenk R; Itälä-Remes M; Pavone V; Fouillard L; Maertens J; Bron D; Pouli A; Schroyens W; Schönland S; Garderet L; Yakoub-Agha I; Kröger N
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2134-2142. PubMed ID: 31288095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extramedullary disease in multiple myeloma.
    Bansal R; Rakshit S; Kumar S
    Blood Cancer J; 2021 Sep; 11(9):161. PubMed ID: 34588423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural history of multiple myeloma with de novo del(17p).
    Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Dispenzieri A; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
    Blood Cancer J; 2019 Mar; 9(3):32. PubMed ID: 30846679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
    Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R
    PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases.
    Deng S; Xu Y; An G; Sui W; Zou D; Zhao Y; Qi J; Li F; Hao M; Qiu L
    Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):286-91. PubMed ID: 25640025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma cell leukemia: from biology to treatment.
    Jelinek T; Kryukov F; Rihova L; Hajek R
    Eur J Haematol; 2015 Jul; 95(1):16-26. PubMed ID: 25778450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
    Hose D; Rème T; Hielscher T; Moreaux J; Messner T; Seckinger A; Benner A; Shaughnessy JD; Barlogie B; Zhou Y; Hillengass J; Bertsch U; Neben K; Möhler T; Rossi JF; Jauch A; Klein B; Goldschmidt H
    Haematologica; 2011 Jan; 96(1):87-95. PubMed ID: 20884712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
    Rajkumar SV
    Am J Hematol; 2013 Mar; 88(3):226-35. PubMed ID: 23440663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Abnormalities in Extramedullary Multiple Myeloma.
    McAvera R; Quinn J; Murphy P; Glavey S
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation.
    Weinstock M; Aljawai Y; Morgan EA; Laubach J; Gannon M; Roccaro AM; Varga C; Mitsiades CS; Paba-Prada C; Schlossman R; Munshi N; Anderson KC; Richardson PP; Weller E; Ghobrial IM
    Br J Haematol; 2015 Jun; 169(6):851-8. PubMed ID: 25833301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of central nervous system involvement in relapsed and refractory multiple myeloma.
    Abdallah AO; Atrash S; Shahid Z; Jameel M; Grazziutti M; Apewokin S; Kumar NS; Restrepo A; Waheed S; Van Rhee F; Heuck CJ; Johann D; Barlogie B; Usmani SZ
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):211-4. PubMed ID: 24373936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extramedullary disease in multiple myeloma: a systematic literature review.
    Bladé J; Beksac M; Caers J; Jurczyszyn A; von Lilienfeld-Toal M; Moreau P; Rasche L; Rosiñol L; Usmani SZ; Zamagni E; Richardson P
    Blood Cancer J; 2022 Mar; 12(3):45. PubMed ID: 35314675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of multiple myeloma with navicular bone involvement.
    Yildizhan E; Kaynar L; Tiren N; Canoz O; Eser B
    Scott Med J; 2017 Nov; 62(4):152-155. PubMed ID: 28959919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma.
    Weinhold N; Kirn D; Seckinger A; Hielscher T; Granzow M; Bertsch U; Egerer G; Salwender H; Blau IW; Weisel K; Hillengass J; Raab MS; Hose D; Goldschmidt H; Jauch A
    Haematologica; 2016 Mar; 101(3):e116-9. PubMed ID: 26611471
    [No Abstract]   [Full Text] [Related]  

  • 18. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations.
    Fassas AB; Muwalla F; Berryman T; Benramdane R; Joseph L; Anaissie E; Sethi R; Desikan R; Siegel D; Badros A; Toor A; Zangari M; Morris C; Angtuaco E; Mathew S; Wilson C; Hough A; Harik S; Barlogie B; Tricot G
    Br J Haematol; 2002 Apr; 117(1):103-8. PubMed ID: 11918539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research Progress on Multiple Myeloma with Extramedullary Disease].
    Wang L; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):945-8. PubMed ID: 27342539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
    Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.